Clinical Gene Networks AB

Unikt samarbete mellan Clinical Gene Networks AB och Merck&Co

Pressmeddelande   •   Apr 27, 2009 10:01 CEST

Clinical Gene Networks AB (CGN), a Swedish liability company situated in Stockholm at the Karolinska Institute site, has settled entered into a collaborative agreement with Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc., to work jointly on the sharing of know-how and databases in an effort to improve the understanding of cardiovascular disease, with particular emphasis on atherosclerosis. The collaboration also has a specific aim to identify cross-tissue gene networks and their impact on complex diseases such as atherosclerosis.The collaboration also has a specific aim to identify cross-tissue gene networks and their impact on complex diseases such as atherosclerosis.

Contact persons CGN: CEO, Johan Björkegren, +46733-568181, CSO Jesper Tegnér +46703-282989